From forums to facts
Claims Center
We do not mock the question or hide the uncertainty. Each review explains why a claim feels believable, what the evidence says, what would change the answer, and where professional care belongs.
"If a peptide works in animals, it probably works in people."
Animal studies can reveal mechanisms and justify human trials, but they cannot establish human benefit, safe exposure, or the balance of benefit and harm.
Read the evidence review ->Natural does not mean risk-free"Peptides are natural or already in the body, so they are safer than ordinary drugs."
A substance's presence in the body does not establish the safety of an external product, a different concentration, a modified sequence, repeated exposure, impurities, or use in a person with other conditions.
Read the evidence review ->A label is not human-use authorization"A 'research use only' label makes a peptide legal or acceptable for personal human use."
'Research use only' describes a seller's stated market or intended laboratory context. It does not grant FDA approval, establish a lawful human drug pathway, prove product quality, or create medical supervision.
Read the evidence review ->Not FDA-approved"BPC-157 is FDA-approved now because FDA reviewed it or because a phase 2 trial exists."
BPC-157 is not an FDA-approved drug. FDA compounding review and a recruiting phase 2 trial are real developments, but neither one is a marketing approval.
Read the evidence review ->No reliable human synergy evidence"BPC-157 and TB-500 have proven synergy for injury recovery."
The combination is common in forum discussions, but repeated pairing does not establish synergy. Reliable synergy evidence would require a controlled comparison of each component, the combination, and an appropriate control.
Read the evidence review ->Absence of reports is not evidence of safety"If forums and adverse-event databases show few serious reports, a peptide is probably safe."
Few reports can mean few events, but they can also reflect low use, underreporting, poor product traceability, delayed effects, missing follow-up, or failure to connect a symptom with a product.
Read the evidence review ->